Background {#Sec1}
==========

The importance of the close association between chronic kidney disease (CKD) and cardiovascular disease (CVD), the cardiorenal syndrome, is becoming increasingly recognised among nephrologists and cardiologists \[[@CR1]--[@CR3]\]. The mechanisms underlying this association have been explored during the last decade, identifying an accelerated vascular disease with early endothelial dysfunction \[[@CR4]\], and subsequent vascular calcification progressing to arterial stiffening and remodelling \[[@CR3], [@CR5]--[@CR8]\].

Vitamin D is currently regarded as a hormone with multiple pleiotropic effects, and the deficiency of the activated form in CKD has attracted substantial attention \[[@CR9]--[@CR12]\]. Vitamin D seems to have endothelial protective properties, downregulating both oxidative stress and the inflammatory response, and upregulating the key enzyme for endothelial function, eNOS \[[@CR13]--[@CR17]\]. Treatment or supplementation with vitamin D compounds to CKD patients seems to lower albuminuria \[[@CR18]--[@CR20]\]. Regarding measures of vascular function, several studies and a recent meta-analysis by our group have shown positive effects on endothelial function \[[@CR10], [@CR21]--[@CR24]\], although this might be debated in lower doses \[[@CR25], [@CR26]\]. Regarding measures of arterial stiffness, the next step in the vascular disease process, most \[[@CR27], [@CR28]\] but not all \[[@CR10], [@CR11]\] studies have been negative.

Microparticles are small vesicles shedded from the parent cell membrane as a response to activation of the cell, but also during stress and apoptosis \[[@CR29]--[@CR31]\]. Evidence is emerging showing that MPs are biologically active, affecting cells locally and mediating intercellular communication \[[@CR29], [@CR30], [@CR32]--[@CR34]\]. The mechanism for their release, apoptosis, cell damage or activation, seems to induce different patterns of markers such as CD31, CD62E, CD62P, or CD144 on their surface \[[@CR29], [@CR31], [@CR35]\]. Depending on their origin and surface molecules, they exhibit opposite effects on apoptosis, inflammation and oxidative stress \[[@CR29], [@CR31]--[@CR33], [@CR36], [@CR37]\].

Levels of CD31-positive-CD41-negative (CD31^+^ CD41^**−**^) and CD144-positive (CD144^+^) endothelial MPs (EMPs) correlate with physiological measurements of vascular function, such as flow mediated vasodilatation (FMD) and pulse wave velocity (PWV) \[[@CR38]--[@CR42]\]. The marked endothelial dysfunction in CKD patients is consequently reflected in higher levels of CD144^+^ and CD31^+^CD41^−^EMPs compared to healthy controls \[[@CR38], [@CR43]--[@CR45]\]. For CD144^+^, and CD31^+^CD41^−^ EMPs, elevated levels are associated with cardiovascular morbidity and mortality in atherosclerosis, kidney failure, pulmonary hypertension and heart failure \[[@CR39], [@CR46]--[@CR49]\].

Intercellular adhesion molecule 1 (ICAM-1; CD54) and vascular cell adhesion molecule 1 (VCAM-1; CD106) are expressed on endothelial cells and on EMPs from activated and proinflammatory cells \[[@CR31], [@CR35]\]. They control the recruitment and migration of white blood cells to the site of inflammation and play an important role in the atherosclerotic process \[[@CR50]\]. Some studies indicate that levels of soluble ICAM-1 and VCAM-1 correlate with cardiovascular events and death in CKD patients \[[@CR51]\] \[[@CR52], [@CR53]\], to intima media thickness in hemodialysis (HD) patients \[[@CR54]\], and to measures of dyslipidaemia \[[@CR52], [@CR53]\]. ICAM-1 and VCAM-1 are therefore considered to reflect the level of endothelial proinflammatory and proatherosclerotic activation in the endothelium \[[@CR50]\].

This is a sub-study of the SOLID trial in which we show that active vitamin D attenuates a decline in endothelial function measured by FMD, and reduces levels of proinflammatory cytokines \[[@CR15], [@CR22]\]. The effects of vitamin D treatment on MPs and their expression of surface proteins in CKD patients have until now not been studied. We therefore hypothesized that these protective vascular effects of vitamin D treatment would be reflected in the concentrations of ICAM-1 and VCAM-1 positive MPs, and potentially also in the concentrations of CD62E^+^ EMPs, as well as other cellspecific MPs.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

This is a sub-study of the blood samples collected in the SOLID trial \[[@CR22]\]. Department of Nephrology at Danderyd University Hospital, Stockholm, Sweden, was the base of recruitment, between June 2010 and February 2013. Inclusion criteria were an estimated glomerular filtration rate (eGFR) of 15--59 mL/min/1.73m^2^ (plasma creatinine used in the Modification of Diet in Renal Disease (MDRD) formula), age \> 20 years, a calcium level below 2.6 mmol/L, a plasma PTH level of 3.7--53 pmol/L, a serum albumin above 30 g/L and with no changes in angiotensin converting enzyme inhibitor or angiotensin receptor blocker 2 months before the trial. Most important exclusion criteria were diabetes mellitus or treatment with vitamin D or its analogues, acute renal failure during the last 3 months, uncontrolled hypertension (repeated measures of a brachial blood pressure \> 150/100 mmHg), or other severe disease (severe congestive heart failure, active cancer or AIDS/HIV). The study protocol was approved by the regional Ethics Committee of Stockholm, Sweden. All patients provided written informed consent. The trial was registered on clinicaltrials.gov (SOLID study; NCT01204528) in April 27, 2010.

Study design and procedures {#Sec4}
---------------------------

The complete study design and procedures have already been published \[[@CR22]\] (see Fig. [1](#Fig1){ref-type="fig"}, flow diagram of the solid trial). Patients were included and randomized consecutively and double blinded, to three groups; placebo, 1 μg paricalcitol, or 2 μg paricalcitol daily. Patients were started on 2 weeks of placebo run in, followed by 12 weeks of blinded treatment. Measurements including blood samples were made at baseline and after intervention. Patients came in the morning, fasting (12 h) and rested for 20 min. Venous blood samples were then drawn, for routine chemistry in the hospital laboratory, for centrifugation to platelet poor plasma, and then frozen for later specialized assays, among them MP measurements. MP measurements were performed in research laboratories at Danderyd University Hospital, Stockholm, Sweden. To avoid the influence of sun exposure and vitamin D activation, no patients were randomized during June to August.Fig. 1Flow diagram of the SOLID trial

MP measurements by flow cytometry {#Sec5}
---------------------------------

Frozen (− 80 degrees Celcius) platelet poor plasma (PPP) were thawed in water bath and centrifuged initially at 2,000 g for 20 min at room temperature The supernatant was then centrifuged again at 13,000 g for 2 min at room temperature. Subsequently, 20 μL of the supernatant was incubated in the dark with 5 μl lactadherin-FITC (80 μM, BLAC-FITC, Coatech AB, Klädesholmen, Sweden) that binds to phosphatidylserine (PS), together with 5 μl CD62E-APC (0.25 μg/test, Thermo Fisher Scientific, Waltham, MA, USA), CD41-APC (5 μl, Beckman Coulter, Brea, CA, USA), 5 μl CD62P-PE (0.25 μg/test, Thermo Fisher Scientific, Waltham, MA, USA), 5 μl CD154-APC (0.25 μg/test, Thermo Fisher Scientific, Waltham, MA, USA) and 5 μl CD45-APC (Beckman Coulter, Brea, CA, USA). In addition, the concentrations of 5 μl CD106-PE positive MPs (VCAM-1, Abcam, Cambridge, UK) and 5 μl CD54-PE positive MPs (0.25 μg/ml ICAM-1, Abcam Cambridge, UK) were investigated. ICAM-1 and VCAM-1 were considered as primary analysis, since they are more validated as risk markers. MP profile was considered a secondary analysis.

All samples were measured on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA). The MP gate was determined with Megamix beads (FSC; 0.3 μm, 0.5 μm, 0.9 μm BioCytex, Marseille, FR) and MPs were defined as particles less than 0.9 μm. MPs were categorized by size and lactadherin binding together with cell-specific antibodies, or only size and exposure of CD106 or CD54. Conjugate isotype-matched immunoglobulin (Mouse IgG, FITC, PE, APC; all from Beckman Coulter) with no reactivity against human antigens was used as a negative control to define the background noise of the cytometric analysis. The MP counts are presented as MPs per μL plasma (see Fig. [2](#Fig2){ref-type="fig"} for gating strategy).Fig. 2Microparticle gating strategy. Representative flow cytometric plots demonstrating **a**) MP-gate alignment by beads and a patient sample. **b** Endothelial microparticles labeled with isotope controls and lactadherin-FITC and CD62E-APC. **c** Platelet microparticles labeled with isotope controls and lactadherin-FITC and CD41-APC. All samples were measured on a Gallios flow cytometer

Statistical analyses {#Sec6}
--------------------

All analyses were made according to intention to treat. Equality of variances in the sample was tested by Levene's Test of Equality of Error Variances, and the assumptions for ANOVA were fulfilled for all parameters. Baseline comparisons were performed with oneway ANOVA, with Pearson's chi-squared, and with Fischer's exact test when appropriate. To investigate the effect of treatment on cell-specific MP subtypes, while avoiding multiple comparisons, we used repeated measures two-way MANOVA with time and treatment as independent variables. All MPs with cell specific antibody labelling were included as dependent variables. Post hoc analysis for within group changes was made by repeated measures one way (split by treatment group) MANOVA and in a separate analysis of EMPs by paired t-test. Effects of treatment on the concentrations of ICAM-1 and VCAM-1 positive microparticles were investigated with repeated measures two-way ANOVA. Since our study was the first on the subject, and a sub-study of the SOLID trial, no power calculations were made, and it was thus considered as hypothesis generating. A *p*-value \< 0.05 was considered significant. All analyses were made with SPSS version 24 (IBM Corp. 2016).

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Thirty-six patients were included and randomized to placebo, 1 or 2 μg of paricalcitol. One patient experienced side effects of treatment (placebo) and therefore did not continue on intervention and declined to do the post measurements. No major adverse events were recorded during the study.

Baseline characteristics are presented in Table [1](#Tab1){ref-type="table"}. Included patients were well matched in terms of kidney function and treatment. Neither was there any difference in baseline plasma levels of 25OH-vitamin D, calcium, phosphate or levels of parathyroid hormone (PTH). They were also well matched in vascular parameters such as FMD, PWV, iontophoresis and echocardiographic measures, previously reported in detail \[[@CR22]\]. The placebo group was however slightly older than the 2 μg group (*p* = 0.02). Correlations at baseline were performed, showing no correlation between age and outcome parameters, as well as age and vascular parameters. There was, in absolute numbers, more CV disease in the placebo group, compared to the 2 μg group, but this difference was not statistically significant.Table 1Baseline characteristics*BMI* Body mass index, *CKD* Chronic kidney disease, *CVD* Cardiovascular disease, *TIA* Transient ischaemic attack, *ACE-i* Angiotensin converting enzyme inhibitor, *ARB* Angiotensin receptor blocker, *Ca flow-inh* Calcium flow inhibitor. Values are expressed as mean (SD)

Blood chemistry post treatment {#Sec9}
------------------------------

Results are presented in Table [2](#Tab2){ref-type="table"}. PTH was suppressed by treatment (ANOVA *p* = 0.006) in a dose dependent manner. There was no significant change in phosphate or calcium levels by treatment. However, we saw slightly higher calcium levels in absolute numbers in the 2 μg group. Levels of FGF-23 were not significantly changed by treatment. Estimated GFR was not affected by treatment, but there was numerically a non significant decline in renal function in all groups during the study (repeated measures ANOVA main effect of time *p* = 0.06).Table 2Clinical characteristics and laboratory measurements pre- and post-treatment*BP* Blood pressure, *eGFR* Estimated glomerular filtration rate, Ualb/crea = urine albumin creatinine ratio, *PTH* Parathyroid hormone, *FGF23* Fibroblast growth factor 23. Values are expressed as mean (SD). *P*-value for interaction of treatment and time

ICAM-1 and VCAM-1 positive microparticles {#Sec10}
-----------------------------------------

There were no significant between-group differences in concentrations of ICAM-1^+^ or VCAM-1^+^ MPs before treatment. Concentrations of ICAM-1^+^ MPs demonstrated a significant interaction between time and treatment (repeated measures ANOVA *p* = 0.04), with a rise in MPs expressing ICAM-1 in the placebo group and a decline in the treated groups (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Concentrations of VCAM-1^+^ MPs did not change significantly during the study (repeated measures ANOVA *p* = 0.52) (Table [3](#Tab3){ref-type="table"}).Fig. 3ICAM-1^+^ MP concentrations at baseline and post-treatment show significant interaction between treatment and time, i.e. the change over time was different between the placebo group and treated groupsTable 3MP concentrations pre- and post-treatment*ICAM-1* Intercellular adhesion molecule-1, *VCAM-1* Vascular adhesion molecule − 1, *CD62e*^*+*^ Endothelial MPs, *CD45*^*+*^ Leukocyte MPs, *CD41*^*+*^ Platelet MPs, *CD41*^*+*^*62p*^*+*^ Platelet MPs, *CD41*^*+*^ *154*^*+*^ Platelet MPs. Values are expressed as mean (SD)

Endothelial, platelet and leukocyte microparticles (EMPs, PMPs and LMPs) {#Sec11}
------------------------------------------------------------------------

Concentrations of EMPs, PMPs and LMPs were all well matched between groups at baseline. The repeated measures two-way MANOVA including CD62E^+^ EMPs, CD41^+^ PMPs, CD41^+^ CD62P^+^ PMPs, CD41^+^CD154^+^ PMPs and CD45^+^ LMPs showed a significant decline in MP counts during the study (*p* = 0.001 for the main effect of time), with a non significant interaction between treatment and time (repeated measures MANOVA *p* = 0.08). However, due to the clear pattern seen, further analyses with one-way repeated measures MANOVA were performed. They showed sustained levels in the 2 μg group (*p* = 0.85), and significantly decreasing levels for the 1 μg group (*p* = 0.04), and placebo (*p* = 0.005) (Fig. [4](#Fig4){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). Since our study focused more on the change in EMP levels, further analysis was performed on CD62E^+^ EMPs. There was a significant decrease in CD62E^+^ EMPs across all groups (*p* \< 0.001) during the study, as for all MPs. For CD62E^+^ EMPs, this was however due to a significant decline in only the placebo group (paired t-test, *p* = 0.002). The concentrations of CD62E^+^ EMPs in the 1 and 2 μg groups did not decrease significantly during the study (1 μg, paired t-test, *p* = 0.10, and 2 μg, *p* = 0.3), but did change slightly in a dose dependent manner in absolute numbers (Fig. [5](#Fig5){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}).Fig. 4Sum of EMP, PMP and LMP concentrations at baseline and post-treatment show significant decline for placebo and 1 μg, but not for 2 μg of paricalcitol treatmentFig. 5EMP concentrations at baseline and post-treatment show significant decline in the placebo group, but not in paricalcitol treated patients

Discussion {#Sec12}
==========

Paricalcitol treatment for 12 weeks to CKD patients in stage 3--4 induces a decline relative to placebo in concentrations of ICAM-1 positive MPs, where soluble ICAM-1 is a marker known to be implicated in atherosclerosis and to correlate with risk of future cardiovascular events \[[@CR53]\]. This is in line with our previous findings in the SOLID study, with a maintained endothelial function and reduced inflammation in patients treated with 2 μg of paricalcitol \[[@CR15], [@CR22]\]. These findings were also accompanied by sustained concentrations of cell activation induced EMPs and PMPs, as well as levels of LMPs in the 2 μg treatment group, whereas the MP concentrations in the placebo group decreased for all measured cell specific MPs.

It is of importance to know the subtype of MPs investigated to correctly interpret the results, however this is not always clearly stated. For EMPs, Jimenez et al. \[[@CR35]\] showed that when apoptosis was induced in endothelial cells in-vitro, activation markers on the endothelial cells and cell activation induced CD62E+ EMPs remained stable, while apoptotic markers and the production of apoptotic EMPs increased rapidly. In patients with acute coronary syndrome, three studies have documented a pattern with high concentrations of apoptotic EMPs \[[@CR35], [@CR55], [@CR56]\], probably reflecting acute endothelial cell injury due to ischemia, whereas other MP subtypes were not described.

There are few studies performed that investigate changes in EMPs and their expression by an intervention. Two in-vitro studies \[[@CR14], [@CR17]\] on endothelial cell lines show lower levels of CD31+ EMPs after vitamin D treatment likely due to a protective effect against apoptosis. Two clinical studies on atorvastatin treatment in non-CKD patients have shown a rise in CD144^+^ EMPs by treatment \[[@CR57], [@CR58]\]. Interestingly, statins are believed to have similar endothelial cell protective effects as vitamin D, reducing oxidative stress and upregulating eNOS \[[@CR59]\]. Mobarrez et al. interpreted the statin induced rise in EMPs as a protection against apoptosis, and a more healthy and reactive endothelium. On the other hand, Tehrani et al. \[[@CR58]\] have shown an impaired endothelial dependent microcirculatory function in patients with type 1 diabetes during high dose statin treatment, although in that case it might have been due to an impaired glucose control. Augustine et al. \[[@CR60]\] reported in a study of apoptotic EMP- and PMP-response to dobutamine stress echocardiography, that patients with signs of coronary disease (wall motion abnormalities) did not react with elevated CD31^+^ EMPs or PMPs, whereas patients with a normal stress-test did. These results seem to indicate, at least in some settings, that a dysfunctional endothelium might be less reactive, not producing more MPs in response to stress or other events, in the same way as in healthy controls or treated patients.

Concentrations of MPs expressing ICAM-1 in our patients were declining in the treatment groups with a significant interaction with treatment. ICAM-1 is an activation marker, implicated in the atherosclerotic process \[[@CR50]\] and is believed to correlate to atherosclerotic events \[[@CR51]--[@CR53]\]. Our results are in line with previous findings \[[@CR21], [@CR61]\] of decreasing levels of soluble ICAM-1 with vitamin D treatment in patients with CKD, believed to be a sign of a less pro-atherosclerotic endothelium.

We found an overall decline in the levels of cell-specific MP subtypes, however with sustained levels for the 2 μg treatment group. For CD62E^+^ EMPs there were sustained levels in both treatment groups with decreasing levels in placebo treated patients. This finding is especially interesting since we have previously shown, in these patients, that treatment maintained endothelial function measured by FMD \[[@CR22]\]. In line with former interventional studies, decreasing levels of activation-induced EMPs may indicate less reactive potential in a chronically dysfunctional endothelium. Vitamin D treatment might then be protective against this ongoing process. However, these findings demand further research.

High levels of CD31^+^ 41^−^ and CD144^+^ EMPs seem to correlate to endothelial dysfunction and to future risk of cardiovascular morbidity and mortality \[[@CR38]--[@CR42], [@CR46]--[@CR49]\]. It is however unknown how changes over time relate to risk and treatment. Previous results are difficult to directly relate to our findings since only one of these studies investigated CD62^+^ EMPs \[[@CR46]\], and since we, in the present study, did not use healthy controls. However, we do have a well characterized population, with sustained endothelial function and decreasing levels of proinflammatory cytokines in the 2 μg treatment group. Our findings with reduced concentrations of ICAM-1 positive MPs and sustained EMP, PMP and LMP concentrations might, in the light of our previous findings, be interpreted as a protective effect of paricalcitol on the vasculature.

The main limitations of the present randomized double blind study is that it is of short duration and with a small number of participants, limiting the generalizability. Despite the randomized design, there were differences in age, and differences in absolute numbers of CV disease in the three groups. Since all outcome measures, as well as measures of kidney function and laboratory parameters, were well matched at baseline, we do not believe that these differences have affected the results. However, we do acknowledge this as a limitation since age and previous CV disease is of great importance in the development of vascular disease. Samples were frozen and thawed for the analyses, however the techniques used should be robust for this issue. MPs are still new as biomarkers and there are very few interventional studies performed, making the results more difficult to interpret. This is to our knowledge the first study reporting on changes in MP concentrations in a randomized interventional trial in CKD patients, and our findings needs further investigations.

Conclusions {#Sec13}
===========

In this study we show that active vitamin D treatment with paricalcitol in CKD patients reduce concentrations of ICAM-1 positive MPs, indicating a less pro-atherosclerotic endothelium. The previously reported maintained endothelial function measured by FMD in the 2 μg treatment group, was associated with maintained concentrations of cell-activation induced EMPs, PMPs and LMPs, which might be interpreted as markers of an endothelium with preserved reactive potential.
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